CNTB

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and six months ended June 30, 2026, and provided a business update. “During the second quarter, we achieved important milestones with the completion of enrollment in both our Phase 2 Seabreeze STAT asthma and chronic obstructive pulmonary disease (COPD) studies.

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, as an adjunct to standard of care for acute exacerbations in participants with asthma and type 2 inflammation. “Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of asthma,” said Barry Quart, Pharm.D.

Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –

Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects pivotal Phase 2 data in mid-2026.

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size. “Based on the DMC's review of interim efficacy results from our ongoing Seabreeze STAT acute asthma and COPD studies, enrollment will continue as planned with no change in sample size,” said Barry Quart, Pharm.D.